Conclusion of a non-exclusive discount contract according to § 130a Abs. 8 SGB V on medicines with the active substance abatacept (ATC-Code: L04AA24) within the period from 1.1.2020 to 31.12.2021 with possibility of contract conclusion during the term ("open-ended") house-model ").
The contracting parties can be viewed at: https://www.aok-gesundheitspartner.de/nds/arzneimittel/rabatt/index_03504.html?bl=nds
The AOK - The Health Insurance Fund for Lower Saxony intends until the entry into force of exclusive contracts following a public tender in accordance with the provisions of Part 4 of the GWB, non-exclusive drug discount agreements on the active substance abatacept (ATC code: L04AA24) with all possible market participants (pharmaceutical companies or communities pharmaceutical entrepreneur) in the so-called "open-house model".
The AOK Lower Saxony will make no selection decision and submit an identical contract offer to every interested pharmaceutical company. In the open-house model, uniform conditions apply to all participants. Contract contents, conditions and access procedures are uniform - individual negotiations are generally not conducted. The contract terms are a maximum of twenty-four months, the earliest date of contract is 1.1.2020. All contracts end no later than 31.12.2021, regardless of the date of the respective contract. An accession or a contract can be made within the twenty-four month period on the first of each month. There is a right of termination six weeks to the end of each month. The AOK Niedersachsen reserves the right to replace the non-exclusive open-house discount agreements with exclusive discount agreements during the contract period. With the entry into force of exclusive, exclusive discount agreements, the open-house contracts will be terminated in accordance with the contractual agreement, ie the open-house contracts will end automatically. According to the experience of the AOK Niedersachsen, exclusive rebate agreements usually enter into force 6 to 8 months after the publication of the relevant call for tenders in the Supplement to the Official Journal of the European Union. Future contractors in the open-house model are invited to regularly consult the supplement to the Official Journal of the European Union for these calls for tenders.
Interested pharmaceutical companies may request the contract documents and the terms of contract at the contact address listed under I.1).
Contracts for the active substance abatacept will be concluded for the first time with effect from 1.01.2020. Interested parties wishing to become contract partners on this date must submit the contract documents to be submitted by 27.11.2019 at the address specified in the contract documents. It depends on the access at the AOK Lower Saxony. Subsequent contracts are possible during the twenty-four month maximum term on the first of each month. Organizationally, an advance of usually 35 calendar days on the part of the AOK is necessary to carry out the necessary work, eg. For example, to be able to guarantee the contract notification in the Lauer-Taxe®. The exact deadlines are announced with the contract documents. This publication does not constitute a public contract within the meaning of the Directive (2014/24 / EU) or the GWB. In order to ensure the widest possible transparency of the intended contracts, it is published in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure "open procedure", are solely due to the use of this announcement form and the publication platform. A further meaning, in particular a submission subcontracting regulations, as far as they are not obligatory for legal reasons, is not connected with this.